BLSM (BlossomHill Therapeutics) Preferred Dividends: $0.00 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BLSM BlossomHill Therapeutics Inc BLSM
11 GF Score
Price $16.55
View Full Analysis

What is BlossomHill Therapeutics Preferred Dividends?

BlossomHill Therapeutics BLSM +3.12% 11 Preferred Dividends is $0.00 Mil as of Dec. 2025. GuruFocus rates BLSM with a GF Score™ of 11/100.

Preferred dividend is a dividend that is accrued and paid on a company's preferred shares. BlossomHill Therapeutics's preferred dividends for the six months ended in Dec. 2025 was $0.00 Mil. Its preferred dividends for the trailing twelve months (TTM) ended in Dec. 2025 was $0.00 Mil.

BlossomHill Therapeutics  (NAS:BLSM) Preferred Dividends Explanation

In the event that a company is unable to pay all dividends, claims to preferred dividends take precedence over claims to dividends that are paid on common shares.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Preferred Dividends for the trailing twelve months (TTM) ended in Dec. 2025 was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BlossomHill Therapeutics Preferred Dividends Historical Data

* Premium members only.

The historical data trend for BlossomHill Therapeutics's Preferred Dividends can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BlossomHill Therapeutics Preferred Dividends Chart

BlossomHill Therapeutics Annual Data
Trend Dec24 Dec25
Preferred Dividends
0.00 0.00

BlossomHill Therapeutics Semi-Annual Data
Dec24 Dec25
Preferred Dividends 0.00 0.00
BLSM
11GF Score
BlossomHill Therapeutics Inc BLSM
Preferred Dividends is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BlossomHill Therapeutics Preferred Dividends Calculation

A dividend that is accrued and paid on a company's preferred shares.

Frequently Asked Questions Learn more about Preferred Dividends →
What does a Preferred Dividends of $0.00 Mil mean?
BlossomHill Therapeutics (BLSM) has a Preferred Dividends of $0.00 Mil as of Dec. 2025. Preferred Dividends is the total amount a company pays out as dividends on its preferred shares. View historical data on BlossomHill Therapeutics and its competitors.
Is BlossomHill Therapeutics' Preferred Dividends too high?
BlossomHill Therapeutics' current Preferred Dividends is $0.00 Mil. Overall, BlossomHill Therapeutics has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does BlossomHill Therapeutics' Preferred Dividends compare to ?
BlossomHill Therapeutics' Preferred Dividends of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Preferred Dividends for a Biotechnology company?
A good Preferred Dividends depends on the Biotechnology industry context. However, Preferred Dividends should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Preferred Dividends mean?
A high Preferred Dividends can signal that a stock is expensive relative to its fundamentals. Preferred Dividends is the total amount a company pays out as dividends on its preferred shares. View historical data on BlossomHill Therapeutics and its competitors. BlossomHill Therapeutics's current Preferred Dividends is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BlossomHill Therapeutics stock overvalued right now?
BlossomHill Therapeutics (BLSM) has a current Preferred Dividends of $0.00 Mil. The current Preferred Dividends is $0.00 Mil. BlossomHill Therapeutics' overall GF Score™ is 11/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Preferred Dividends calculated?
Preferred Dividends is calculated from a company's financial statements. For BlossomHill Therapeutics (BLSM), the current Preferred Dividends is $0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BlossomHill Therapeutics Business Description

Comparable Companies
Address 10255 Science Center Drive, Suite 200, San Diego, CA, USA, 92121
BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying its intentional, chemistry-based approach to develop small molecule medicines that address unmet medical needs in cancer treatment. Its product pipeline includes two clinical-stage programs: BH-30643, an investigational, non-covalent, macrocyclic, brain active, mutant-selective OMNI-EGFR inhibitor for the treatment of epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), and BH-30236, an investigational macrocyclic CDC-like kinase (CLK) inhibitor being evaluated first in relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndromes (HR-MDS), and the preclinical-stage product candidate BH-501284 targeting activated KRAS.
11GF Score

Get the complete analysis for BLSM

Preferred Dividends is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$16.55
Price